Timber Pharmaceuticals Receives European Orphan Drug Designation for TMB-001 in X-Linked Recessive Ichthyosis
24. Februar 2023 08:00 ET
|
Timber Pharmaceuticals
Company Progressing With Pivotal Phase 3 ASCEND Clinical Trial in the U.S., Canada, Italy, France, and Germany BASKING RIDGE, NJ, Feb. 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber...
Timber Pharmaceuticals to Host Investor Business Briefing: Milestone Achievements and Forward Outlook
14. Dezember 2022 08:30 ET
|
Timber Pharmaceuticals
Virtual Business Briefing With Q&A to be Webcast on December 20, 2022 at 10:30 am ET BASKING RIDGE, NJ, Dec. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc....
Timber Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards
09. Dezember 2022 16:05 ET
|
Timber Pharmaceuticals
BASKING RIDGE, NJ, Dec. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company...
Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2022 Financial Results
14. November 2022 08:00 ET
|
Timber Pharmaceuticals
-Timber Received Orphan Designation from European Commission for Lead Asset TMB-001- -Recruitment for the pivotal Phase 3 ASCEND clinical trial continues to progress; expected to enroll more...
Timber Pharmaceuticals, Inc. Announces 1-for-50 Reverse Stock Split
08. November 2022 12:10 ET
|
Timber Pharmaceuticals
BASKING RIDGE, NJ, Nov. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE American: TMBR) ("Timber" or the "Company"), a clinical-stage biopharmaceutical company...
Timber Pharmaceuticals Announces Halt of Common Stock Trading
03. November 2022 08:22 ET
|
Timber Pharmaceuticals
Compliance with NYSE Listing Requirements Contingent on Stockholder Approval of Reverse Stock Split at Special Meeting of Stockholders on November 7, 2022 and Consummation of Reverse Stock Split ...
Timber Pharmaceuticals Receives European Orphan Designation for Autosomal Recessive Congenital Ichthyosis & Positive Comments on Pediatric Investigation Plan for TMB-001 in Autosomal Recessive CI & X-Linked Recessive Ichthyosis
25. Oktober 2022 08:00 ET
|
Timber Pharmaceuticals
- Regulatory Milestones Improve Path to Filing a European Marketing Authorization Application -- Company Plans to Submit Additional Application for Orphan Designation in Europe for TMB-001 for the...
Timber Pharmaceuticals Announces $1.3 Million Registered Direct Offering
03. Oktober 2022 09:00 ET
|
Timber Pharmaceuticals
BASKING RIDGE, NJ, Oct. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company...
Timber Pharmaceuticals Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital Ichthyosis
14. September 2022 08:00 ET
|
Timber Pharmaceuticals
European Commission expected to issue its decision on orphan designation in approximately 30 days BASKING RIDGE, NJ, Sept. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber...
Timber Pharmaceuticals Announces Notification of NYSE American Continued Listing Deficiency
29. August 2022 16:05 ET
|
Timber Pharmaceuticals
BASKING RIDGE, NJ, Aug. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company...